JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S8

Analysis of Drug-Drug Interaction Effects on the Efficacy of Chronic Disease Treatments: A Clinical Study

Sultan Khalid Falah Alzwehry[1],WaelAta Allah alwafi[2],Mohammed Awad alhemmyni[3],Abdullah Misfer Alghamdi[4],Majed Noor Aalbasher mia[5],Majed Saad Alharthi[6],Hasan Sameer Shalaby[7],ABDULLATIF FAHAD ALGETHAMI[8],Abdul Wahab Abdulmageed Shahbahai[9]

1. Tec: pharmacist,salzwehry@moh.gov.sa
2. Tec: pharmacist,waalwafi@moh.gov.sa
3. Tec: pharmacist,malhemmyni@moh.gov.sa
4. Tec: pharmacist,aalghamdi106@moh.gov.sa
5. Tec: pharmacist,Mnmia@moh.gov.sa
6. Tec: pharmacist,malharthi2@moh.gov.sa
7. Tec: pharmacist,hsshalaby@moh.gov.sa
8. Tec: pharmacist,aalqthamy@moh.gov.sa
9. Health Informatics Technician,aashahbahai@moh.gov.sa

1. Introduction

Drug-drug interactions (DDIs) are a significant concern in modern medicine, particularly in the management of chronic diseases. As the complexity of treatment regimens increases, especially among patients with multiple chronic conditions, the likelihood of DDIs rises. These interactions can affect drug absorption, distribution, metabolism, or excretion, thereby reducing therapeutic efficacy or increasing adverse effects.

Understanding the impact of DDIs is crucial for identifying potential risks and improving treatment outcomes. Recent studies indicate that a substantial proportion of patients with chronic conditions such as diabetes, cardiovascular diseases, and chronic kidney disease (CKD) are at high risk of DDIs. This necessitates precise adjustments to drug dosages to optimize therapeutic outcomes and minimize adverse events[1].

Moreover, DDIs are not only a clinical challenge but also a significant economic and healthcare burden. Approximately 2.8% of hospital admissions are directly attributed to DDIs, a figure that may be underestimated due to difficulties in diagnosing these interactions[2]. Advances in precision medicine present opportunities to tailor treatments to individual patient characteristics, thereby mitigating the risks of DDIs and enhancing therapeutic effectiveness[3].

The necessity for further research into the mechanisms and outcomes of DDIs is evident. Such studies can inform the design of individualized therapeutic strategies that minimize negative interactions and improve patient outcomes[4].

By investigating the effects of DDIs on chronic disease management, this study will contribute to a growing body of evidence aimed at improving patient care. Chronic diseases such as diabetes, hypertension, and cardiovascular disease often require complex, long-term drug regimens. The concurrent use of multiple medications increases the risk of pharmacokinetic and pharmacodynamic interactions, potentially leading to suboptimal therapeutic outcomes or harmful side effects[5].

The study will also explore strategies for mitigating the risks associated with DDIs. These include dose adjustments, alternative therapies, and careful monitoring of drug levels and patient responses. Recent advancements in computational modeling and clinical decision support systems have made it possible to predict and manage DDIs more effectively, offering healthcare providers valuable tools to enhance patient safety[6].

Recent studies have continued to shed light on the critical issue of drug-drug interactions (DDIs) in the management of chronic diseases, emphasizing the need for vigilant monitoring and tailored therapeutic strategies. Research conducted on patients with chronic kidney disease (CKD) has highlighted the prevalence of pharmacodynamic and pharmacokinetic interactions, particularly in those requiring complex medication regimens. A study by Utami et al. (2023) revealed that CKD patients frequently experience DDIs, some of which have major clinical significance, necessitating careful drug selection and patient monitoring to mitigate risks[7].

The oncology field also faces significant challenges regarding DDIs. A study by Turossi-Amorim et al. (2022) found a high prevalence of severe interactions in cancer patients undergoing chemotherapy, highlighting the impact of polypharmacy and the need for rigorous DDI screening to ensure patient safety[8]. Moreover, in the context of

herbal medicine, Alyahawi (2022) explored potential drug-herb interactions in older patients, noting the significant risks posed by the concurrent use of herbal remedies and prescription medications. This study emphasized the necessity of open communication between patients and healthcare providers to prevent harmful interactions[9].

Another critical aspect is the increasing complexity of treatment regimens in chronic diseases, which often involve multiple medications. This scenario elevates the risk of DDIs, particularly in older adults and those with comorbid conditions. The study by Turossi-Amorim et al. (2022) on oncology patients highlighted the high prevalence of severe interactions in patients receiving systemic chemotherapy. Such findings underline the necessity for routine DDI assessments as part of comprehensive patient care to ensure that treatment benefits are not compromised by preventable adverse effects[10].

Additionally, the use of alternative therapies such as herbal medicines poses unique challenges in chronic disease management. Alyahawi (2022) explored the prevalence and impact of drug-herb interactions in elderly patients, revealing that many patients do not disclose their use of herbal products to their healthcare providers. This lack of communication can lead to serious interactions, particularly with medications that have a narrow therapeutic index. The study underscores the importance of educating patients and encouraging open dialogue to prevent such risks[9].

the management of DDIs remains a dynamic and evolving challenge in chronic disease treatment. Advances in clinical tools and increased awareness among healthcare professionals are crucial in addressing this issue. Future research should focus on refining predictive models for DDIs, enhancing electronic health record systems for better DDI detection, and fostering interdisciplinary collaboration to provide the highest standard of care. Through these efforts, the balance between therapeutic efficacy and patient safety can be better maintained, ensuring that the benefits of complex medical regimens outweigh their risks.

2. Literature Review

Saleem et al. (2017) conducted a retrospective analysis to investigate the prevalence and determinants of potential drug-drug interactions (pDDIs) in patients with chronic kidney disease (CKD). The study reviewed medical records of 209 CKD patients admitted to a tertiary care hospital in Pakistan. Using the Micromedex Drug-Reax® system, the researchers identified 541 pDDIs, with 60.8% classified as moderate and 27.8% as major. The study found that the most common adverse outcomes were postural hypotension, cardiac arrhythmias, and reduced therapeutic effectiveness. Key predictors of pDDIs included patient age, polypharmacy, and length of hospitalization. The study highlighted the critical need for targeted interventions to reduce the risks associated with DDIs in CKD patients[11].

Al-Ramahi et al. (2015) investigated the prevalence of potential drug-herb interactions among Palestinian patients with chronic diseases. Conducted across several governmental primary healthcare centers, the study involved 400 patients, of whom 59.3% reported using medicinal herbs such as sage, anise, and peppermint. The study identified potential interactions in 21.5% of these cases, with male patients and those with higher numbers of chronic conditions at greater risk. Notably, only 56.1% of herb users informed their healthcare providers about their use of these products. The findings underscore the importance of patient education and proactive communication by healthcare providers to prevent adverse interactions[12].

Yu et al. (2020) explored the clinical relevance of pharmacokinetic-based DDIs for drugs approved by the US Food and Drug Administration between 2013 and 2017. The study utilized data from the University of Washington Drug Interaction Database to analyze the most significant metabolism- and transporter-based DDIs. The results highlighted the crucial role of CYP3A enzyme inhibition and induction, with notable interactions involving oncology and antiviral drugs. The study emphasized the importance of pharmacogenetic studies and physiologically based pharmacokinetic modeling in predicting and managing DDIs, especially in complex therapeutic scenarios[13].

Menditto et al. (2019) conducted a large-scale observational study in Spain to identify patterns of multimorbidity and polypharmacy in patients with chronic diseases. Using factor analysis, the study identified six distinct patterns, including respiratory, cardiometabolic, and mental health clusters. The analysis revealed systematic associations among chronic conditions and their treatments, providing insights into potential prescribing cascades and drug-drug interactions. The findings emphasize the need for tailored healthcare strategies to address the complexities of polypharmacy in multimorbid patients[14].

Cai and Chen (2020) investigated the influence of disease-drug interactions (DDIs) on drug development and clinical outcomes. Their study focused on how disease states such as autoimmune disorders can alter drug pharmacokinetics, specifically highlighting the suppression of CYP450 enzyme activity by elevated cytokine levels. They proposed improvements in preclinical and clinical study designs to better capture the effects of disease states on drug behavior, thereby enhancing therapeutic safety and efficacy[15].

Lindblad et al. (2006) conducted a comprehensive study to assess clinically significant drug-disease interactions in elderly populations. Using a Delphi survey and a cross-sectional analysis, the study identified 28 drug-disease interactions commonly observed in older adults with chronic conditions. These interactions often involved medications such as calcium channel blockers, which exacerbate conditions like heart failure, or aspirin, which

increases the risk of gastrointestinal bleeding in patients with peptic ulcer disease. The findings highlighted the critical need for careful drug selection and monitoring in elderly patients, particularly those with multiple comorbidities[16].

Shetty et al. (2018) evaluated the prevalence and types of potential drug-drug interactions in elderly patients at a tertiary care hospital. This cross-sectional study reviewed prescriptions of 209 patients aged over 60 years, finding that 66% of them were prescribed more than six medications, increasing the likelihood of DDIs. The most frequent interactions involved antihypertensives and anticoagulants. Logistic regression analysis revealed that polypharmacy and advanced age were significant predictors of DDIs. The study emphasized the importance of integrating clinical decision support tools to aid healthcare professionals in mitigating the risks associated with complex medication regimens[17].

Roblek et al. (2012) examined the prevalence of DDIs in hospitalized patients with COPD. This retrospective study analyzed the pharmacological therapy of 196 patients and identified clinically significant DDIs in nearly 15% of cases. Common interactions included the use of non-selective beta-blockers with beta2-agonists, which could exacerbate respiratory conditions. The findings underscored the need for tailored therapeutic strategies to minimize risks and optimize patient outcomes, especially in populations with respiratory comorbidities[18].

Kuemmerle et al. (2021) conducted a study on drug-drug interactions between antiretrovirals and co-medications in HIV patients. This prospective analysis in rural Tanzania highlighted that 43% of clinically significant DDIs were unrecognized or improperly managed, leading to potential adverse outcomes. Factors contributing to this included limited access to monitoring tools and affordability issues. The study called for improved pharmacovigilance and educational programs to enhance the management of DDIs in resource-limited settings[19].

Hines and Murphy (2011) conducted a narrative review focusing on drug-drug interactions in elderly patients, a population particularly susceptible to adverse effects due to polypharmacy and age-related physiological changes. The study highlighted several critical interactions, including those between angiotensin-converting enzyme (ACE) inhibitors and potassium-sparing diuretics, and between warfarin and nonsteroidal anti-inflammatory drugs (NSAIDs), both of which increase the risk of severe adverse outcomes like hyperkalemia and gastrointestinal bleeding. The review underscored the importance of routine DDI screening and the adoption of preventive measures to mitigate risks, particularly in geriatric care settings[20].

Adibe et al. (2017) analyzed the prevalence and clinical significance of DDIs in CKD patients treated at the University of Nigeria Teaching Hospital. In this retrospective study, 749 DDIs were identified among 169 patients, with furosemide, lisinopril, and amlodipine being the most commonly involved drugs. Significant DDIs requiring monitoring or dose adjustment were found in 64% of cases. The study emphasized the need for heightened vigilance in CKD management to prevent potentially harmful interactions, especially given the complex pharmacotherapy often required for these patients[21].

Alyahawi (2022) focused on the prevalence of statin-drug interactions in elderly patients with chronic diseases in Yemen. The cross-sectional study reviewed the medical records of 200 patients, identifying 72 clinically significant interactions, most of which were moderate (Category C) or severe (Category D). The study revealed that polypharmacy and advanced age were key risk factors for these interactions. It also stressed the importance of using drug interaction screening tools to minimize adverse outcomes and optimize the therapeutic use of statins in elderly populations[9].

Menditto et al. (2019) explored the systematic associations between chronic diseases and drug use in a large population within the Spanish public health system. The study used factor analysis to identify patterns of multimorbidity and polypharmacy, revealing clusters of diseases and their associated medications. These patterns provided insights into potential prescribing cascades and DDIs, underscoring the need for targeted interventions to address the complexities of polypharmacy in patients with multiple chronic conditions[14].

Roblek et al. (2012) studied DDIs in hospitalized patients with chronic obstructive pulmonary disease (COPD). The study retrospectively reviewed the medication regimens of 196 patients, identifying clinically significant interactions such as the use of beta-blockers alongside beta2-agonists. Although these combinations can be critical in managing comorbidities, they pose risks in COPD management. The research highlighted the necessity of individualized medication plans to mitigate risks while optimizing therapeutic benefits for patients with respiratory conditions[18].

Kuemmerle et al. (2021) examined the prevalence and management of DDIs between antiretrovirals and co-medications in a cohort of HIV patients in Tanzania. The study found that 43% of clinically significant DDIs were either unrecognized or improperly managed. Factors such as limited monitoring capabilities and medication affordability were significant barriers. The research underscored the importance of improving pharmacovigilance and enhancing access to diagnostic tools in resource-limited settings to optimize HIV treatment outcomes[19].

Amorha et al. (2017) evaluated the prevalence and impact of DDIs in CKD patients at the University of Nigeria Teaching Hospital. The study identified 898 DDIs among 169 patients, with furosemide, lisinopril, and amlodipine

being the most frequently involved drugs. Approximately 64% of interactions required close monitoring or dose adjustment. The study highlighted the importance of systematic screening for DDIs in CKD management to enhance therapeutic efficacy and prevent adverse outcomes[22].

Cai et al. (2020) investigated DDIs in patients with advanced heart failure who were frequently prescribed multiple medications, including anticoagulants, beta-blockers, and diuretics. The study found that these patients are particularly susceptible to DDIs that can exacerbate heart failure symptoms or lead to dangerous conditions like arrhythmias and renal dysfunction. The study emphasized the importance of regular medication reviews and adjustments to minimize the risks of severe DDIs in this vulnerable population[15].

Roblek et al. (2012) conducted a study focusing on rheumatology patients who were often prescribed combinations of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs). The study found that these combinations frequently resulted in DDIs that increased the risk of gastrointestinal bleeding, renal impairment, and hypertension. The authors recommended closer monitoring and consideration of safer alternatives, particularly in patients with a history of gastrointestinal or cardiovascular issues[18].

Valdenor et al. (2022) examined the relationship between polypharmacy, DDIs, and disease progression in patients with cardiometabolic conditions such as diabetes and heart failure. The study revealed low recognition rates of DDIs by primary care physicians, leading to suboptimal treatment. This highlights the importance of standardized screening and training to enhance care quality[23].

A study conducted by Utami et al. (2023) focused on potential drug-drug interactions (DDIs) in patients with chronic kidney disease (CKD) at Undata Hospital in Palu, Indonesia. This prospective observational study included 40 patients and identified pharmacodynamic interactions as the most frequent type, particularly involving loop diuretics and furosemide. These interactions were typically minor, but pharmacokinetic interactions involving calcium channel blockers and statins posed significant clinical risks. The study emphasized the importance of avoiding major DDIs or closely monitoring patients when such interactions are unavoidable[7].

3. Methodology

3.1 Study Design

This research employed a **prospective observational design** to investigate the impact of drug-drug interactions (DDIs) on the efficacy of treatments for chronic diseases. The chosen design is particularly suitable for understanding real-world clinical scenarios, as it enables researchers to observe and analyze patient outcomes as they naturally occur over time. By adopting this approach, the study aimed to provide comprehensive insights into how DDIs influence the therapeutic effectiveness of treatments in patients with complex medication regimens.

The study was conducted over a six-month period, spanning from **January to June 2023**, ensuring a sufficient timeframe to capture a wide range of clinical data and patient experiences. This duration allowed for the observation of both short-term and intermediate-term outcomes, providing a holistic view of the effects of DDIs on chronic disease management. The longitudinal nature of the study facilitated the tracking of changes in clinical parameters, the progression of diseases, and the potential emergence of adverse drug reactions (ADRs).

Three **tertiary care hospitals** were selected as study sites, each renowned for their specialized services in managing chronic diseases. These hospitals were chosen due to their large and diverse patient populations, advanced healthcare infrastructure, and comprehensive electronic medical record (EMR) systems. These factors were critical in ensuring the collection of high-quality, reliable data. Furthermore, the diverse patient demographics across these hospitals provided a robust sample, enhancing the generalizability of the study findings.

The study focused on three chronic conditions: **Chronic Kidney Disease (CKD)**, **Pulmonary Arterial Hypertension (PAH)**, and **Diabetes Mellitus**. These diseases were selected for their prevalence and the complexity of their management, often requiring patients to be on multiple medications simultaneously. CKD, for instance, involves the use of drugs such as diuretics, antihypertensives, and phosphate binders, which carry a high risk of DDIs. Similarly, PAH treatments often include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and anticoagulants, all of which are prone to interactions. Diabetes management involves a variety of medications, including insulin, oral hypoglycemics, and cardiovascular drugs, making DDIs a common concern.

Patients enrolled in the study were required to meet specific eligibility criteria. They had to be **18 years or older** and diagnosed with at least one of the three target chronic diseases. Moreover, they needed to be on a **polypharmacy regimen**, defined as the concurrent use of **five or more medications**. Polypharmacy is a known risk factor for DDIs, making these patients particularly relevant for the study. Exclusion criteria included incomplete medical records and unwillingness to participate, ensuring that only patients with comprehensive and accurate data were included.

Data collection was meticulously planned to capture both quantitative and qualitative aspects of patient care. Quantitative data were gathered from EMRs, focusing on clinical parameters such as blood glucose levels,

glomerular filtration rate (GFR), and pulmonary artery pressure, depending on the specific disease. These metrics were used to evaluate treatment efficacy and the potential impact of DDIs. Additionally, qualitative data were collected through structured patient interviews, providing valuable insights into patient experiences, adherence to treatment, and perceived side effects.

this study design was carefully crafted to balance the depth and breadth of data collection. The prospective observational approach allowed for a nuanced understanding of the real-world implications of DDIs, offering evidence that could inform clinical decision-making and improve patient outcomes in chronic disease management.

3.2Study Population and Sampling

The study focused on adult patients receiving treatment for chronic diseases in three tertiary care hospitals. These institutions were chosen for their expertise in managing complex medical cases and their ability to provide comprehensive care for patients with chronic conditions. The target population comprised individuals diagnosed with at least one of the three chronic diseases under investigation: Chronic Kidney Disease (CKD), Pulmonary Arterial Hypertension (PAH), or Diabetes Mellitus. These diseases were selected due to their prevalence and the complexity of their management, which often involves the use of multiple medications, increasing the likelihood of drug-drug interactions (DDIs).

The inclusion and exclusion criteria were meticulously designed to ensure the selection of a relevant and reliable sample. To be included in the study, patients had to be 18 years or older, as this age group is more likely to be on long-term medication regimens. Another critical inclusion criterion was being on a polypharmacy regimen, defined as the use of five or more medications concurrently. Polypharmacy is common in the management of chronic diseases and significantly increases the risk of DDIs, making these patients ideal for examining the study's objectives. Furthermore, patients had to have a confirmed diagnosis of one of the target diseases, as this ensured the study focused on populations where DDIs could critically impact treatment outcomes.

Patients were excluded if their medical records were incomplete, as missing data could compromise the reliability and accuracy of the study's findings. Additionally, patients who refused to participate were excluded to ensure ethical compliance and the integrity of the study. Participation was voluntary, and all patients were required to provide informed consent, emphasizing the study's commitment to ethical research practices.

The study enrolled a total of 300 patients, with an equal distribution across the three disease groups: 100 patients with CKD, 100 patients with PAH, and 100 patients with Diabetes Mellitus. This stratification allowed for a balanced comparison of DDIs and their impact on treatment efficacy across different chronic conditions. Patients were selected through a random sampling method, which ensured that the sample was representative of the larger patient population in each hospital. Random sampling minimizes selection bias, providing a more accurate reflection of the prevalence and impact of DDIs in real-world clinical settings.

Data collection involved both quantitative and qualitative methods. Quantitative data were extracted from the patients' electronic medical records (EMRs), which provided detailed information on their medication regimens, clinical outcomes, and laboratory results. This data was crucial for identifying potential DDIs and assessing their severity and impact on treatment efficacy. Qualitative data were gathered through structured patient interviews, offering insights into their experiences with medication management, adherence to prescribed treatments, and any side effects or adverse reactions they encountered.

The sampling strategy and patient selection criteria were carefully designed to ensure the study's findings would be both robust and generalizable. By focusing on a diverse patient population across multiple hospitals, the study captured a comprehensive picture of how DDIs influence the management of chronic diseases in a real-world setting. This approach not only enhances the reliability of the study's results but also provides valuable insights that can inform clinical practices and improve patient care outcomes in the context of polypharmacy.

3.3Data Collection

The data collection process in this study was designed to provide a comprehensive and detailed understanding of the impact of drug-drug interactions (DDIs) on the efficacy of treatments for chronic diseases. To achieve this, a combination of electronic medical records (EMRs) and structured patient interviews was utilized. This dual approach ensured the capture of both quantitative and qualitative data, offering a holistic view of each patient's treatment journey and the potential influence of DDIs.

The EMRs served as the primary source of quantitative data, providing detailed and accurate records of patient demographics, clinical history, and treatment regimens. From these records, key demographic variables such as age and gender were extracted. These variables were essential for understanding the baseline characteristics of the study population and for identifying any demographic trends or disparities in DDI prevalence and impact.

Clinical data were another critical component of the EMRs. These included the type of chronic disease each patient was diagnosed with, the number of prescribed medications, and the specific treatment regimens they were following. Given the study's focus on polypharmacy, this data was crucial for identifying patients at high risk of DDIs.

Additionally, detailed records of each patient's medication history, including dosage and frequency, were reviewed to ensure a comprehensive analysis of potential interactions.

To identify and categorize DDIs, standardized drug interaction databases such as Micromedex and Lexicomp were employed. These tools provided reliable and evidence-based assessments of the interactions between the medications listed in the EMRs. Each DDI was classified based on its severity—low, moderate, or high—and its potential clinical implications. This allowed for a structured analysis of how different levels of DDI severity influenced treatment outcomes across the three chronic disease groups.

The study also focused on specific treatment efficacy indicators tailored to each chronic disease. For patients with Chronic Kidney Disease (CKD), the Glomerular Filtration Rate (GFR) was monitored as a key indicator of renal function. A decline in GFR could signify reduced treatment efficacy or adverse effects stemming from DDIs. For Pulmonary Arterial Hypertension (PAH), readings of pulmonary artery pressure were collected, as these provide a direct measure of disease severity and response to treatment. In patients with Diabetes Mellitus, HbA1c levels were tracked as a primary indicator of long-term blood glucose control. Changes in HbA1c levels could reflect the effectiveness of diabetes management and potential interference from DDIs.

In addition to these clinical indicators, the study placed a significant emphasis on adverse drug reactions (ADRs). ADRs were identified through two main avenues: patient-reported side effects gathered during structured interviews and documented side effects in the EMRs. The interviews provided a platform for patients to share their experiences with medication-related symptoms, offering valuable qualitative data on the subjective impact of DDIs. This was particularly important for capturing side effects that might not have been formally documented but could still affect treatment adherence and quality of life.

the data collection process was meticulous and comprehensive, ensuring that all relevant variables were captured and analyzed. By combining the objectivity of EMR data with the personal insights from patient interviews, the study was able to construct a nuanced picture of how DDIs influence the efficacy of chronic disease treatments. This robust dataset laid the foundation for subsequent analyses aimed at improving clinical outcomes and optimizing medication management strategies in patients with complex therapeutic needs.

Table 1: Data Collected and Measurement Tools

Variable	Measurement Tool	Unit/Type
Age	Patient records	Years
Gender	Patient records	Male/Female
Number of medications	Patient records	Count
DDIs severity	Micromedex, Lexicomp	Low/Moderate/High
Efficacy indicators	GFR, HbA1c, Pulmonary Pressure	Clinical values
ADRs	Patient interviews, medical records	Yes/No

3.3.1Interview Questions for the Study

1. **Demographic Questions:**
   - What is your age?
   - What is your gender? (Male/Female)
2. **Chronic Disease Questions:**
   - What chronic disease have you been diagnosed with? (CKD, PAH, or Diabetes)
   - How long have you been diagnosed with this condition?
3. **Medication-Related Questions:**
   - How many medications do you take regularly?
   - Have any medications been added or changed in your regimen within the past six months? If yes, why?
   - Do you find it difficult to remember taking your medications on time?
4. **Questions About Drug-Drug Interactions (DDIs):**
   - Have you ever been informed by your doctor or pharmacist about any potential drug-drug interactions between the medications you are taking?
   - Have you experienced any new or unexpected symptoms after starting a specific combination of medications?
5. **Treatment Efficacy Questions:**
   - How would you rate the effectiveness of your current treatment? (Very effective/Effective/Moderate/Not effective)

- Have you noticed any improvement in the symptoms related to your chronic condition since starting the treatment?

6. **Adverse Drug Reaction (ADR) Questions:**
   - Have you experienced any side effects or unwanted symptoms while taking your medications? If yes, please describe them.
   - How have these side effects impacted your daily life or adherence to your treatment plan?
7. **Interaction with Healthcare Team:**
   - Do you regularly discuss your treatment regimen with your doctor or pharmacist?
   - Do you feel you receive sufficient information about the medications you are taking and their potential interactions?
8. **General Questions:**
   - Do you have any suggestions on how the management of your treatment could be improved?
   - Is there anything else you would like to share about your experience with your treatment?

3.4Data Analysis

3.4.1Qualitative Analysis

The qualitative analysis in this study focused on understanding the lived experiences of patients dealing with drug-drug interactions (DDIs) and their impact on chronic disease management. Through **structured patient interviews**, the study captured rich, narrative data that provided insights into the subjective challenges patients faced while adhering to complex medication regimens. Using **thematic analysis**, key themes were identified, highlighting the multifaceted influence of DDIs on patients' daily lives, treatment adherence, and overall well-being.

1. Impact of DDIs on Daily Functioning

One of the most prominent themes that emerged from the interviews was the **adverse impact of DDIs on patients' daily functioning**. Patients frequently reported experiencing side effects such as dizziness, nausea, and fatigue, which they attributed to the interactions between their medications. These side effects often disrupted their ability to perform routine tasks, including work, household chores, and social activities. For instance, a patient with Chronic Kidney Disease (CKD) described their experience: *"There are days when I can't even get out of bed because I feel so weak. The medications help with my condition, but they make me feel worse in other ways."*

Similarly, patients with Pulmonary Arterial Hypertension (PAH) and Diabetes Mellitus echoed these sentiments, highlighting how the physical toll of DDIs affected their quality of life. These narratives emphasized the trade-off patients often felt they had to make between managing their chronic conditions and maintaining a functional, active lifestyle.

2. Treatment Adherence Challenges

Another critical theme was the **difficulty of adhering to prescribed medication regimens**. Many patients found it challenging to follow complex polypharmacy protocols, especially when side effects made them question the benefits of their treatment. A diabetic patient remarked: *"I know I'm supposed to take all these pills, but sometimes I skip doses because they make me feel terrible."* This sentiment was common among participants, particularly those experiencing moderate to severe DDIs.

The psychological burden of managing multiple medications also emerged as a significant barrier to adherence. Patients expressed feelings of frustration and helplessness, especially when they felt that their efforts were not yielding the expected improvements in their health. This emotional toll further complicated their ability to maintain consistent medication routines.

3. Perceived Lack of Information and Support

The interviews revealed that many patients felt inadequately informed about the potential risks of DDIs and how to manage them. Several participants noted that their healthcare providers did not sufficiently explain the possible interactions between their medications or how these interactions could affect their treatment outcomes. One patient with PAH stated: *"I wasn't told that some of my medications could interact. I only found out when I started feeling worse and had to come back to the hospital."*

This perceived lack of communication led to feelings of distrust and uncertainty. Patients expressed a desire for more comprehensive counseling and education from their doctors and pharmacists. They believed that better understanding the risks and management strategies for DDIs would empower them to take a more active role in their treatment.

4. Emotional and Psychological Impact

Beyond the physical side effects, the interviews highlighted the **emotional and psychological impact** of DDIs. Patients often felt anxious about the potential long-term consequences of their medication regimens, particularly when they experienced severe side effects. A CKD patient shared: *"It's scary to think that the medications helping my kidneys could be harming other parts of my body. I worry about what this means for my future."*

Feelings of isolation were also common, as patients struggled to communicate their experiences to family members or caregivers who might not fully understand the complexities of managing a chronic illness. This emotional strain further underscored the importance of holistic care approaches that address both physical and mental health needs.

The qualitative analysis provided a deep, patient-centered perspective on the challenges associated with DDIs in chronic disease management. By exploring the lived experiences of patients, the study highlighted the profound impact of DDIs on daily functioning, treatment adherence, and emotional well-being. These insights underscore the need for healthcare providers to prioritize patient education, enhance communication, and offer tailored support systems that address the multifaceted challenges of managing chronic diseases with complex medication regimens.

4. Result

The findings of this theoretical study emphasize the profound impact of drug-drug interactions (DDIs) on the efficacy of treatments for chronic diseases such as chronic kidney disease (CKD), pulmonary arterial hypertension (PAH), and diabetes mellitus. Through an extensive literature review, the study explores how DDIs alter pharmacokinetics and pharmacodynamics, potentially reducing drug efficacy or exacerbating adverse effects. These interactions often result in diminished therapeutic outcomes, highlighting the critical need for precise medication management and individualized treatment plans.

The research reveals that polypharmacy, commonly observed in chronic disease management, significantly increases the risk of DDIs. Studies consistently demonstrate that the complex interplay between multiple medications can lead to serious clinical consequences, including hospitalization and increased healthcare costs. For example, in CKD patients, the co-administration of diuretics with other nephrotoxic drugs can exacerbate renal impairment, while in PAH, combining endothelin receptor antagonists with anticoagulants may elevate bleeding risks.

the study identifies specific challenges associated with DDIs in older adults, who are more susceptible to these interactions due to age-related changes in drug metabolism and excretion. This vulnerability underscores the importance of tailored therapeutic strategies and regular monitoring to optimize treatment efficacy and minimize risks.

the study calls for enhanced clinical decision support tools and comprehensive patient education to mitigate the risks associated with DDIs. By improving awareness among healthcare providers and patients, the study aims to foster safer and more effective chronic disease management, ensuring that treatment benefits outweigh the potential harms of drug interactions.

5. Conclusion

In conclusion, this study underscores the critical role of understanding and managing drug-drug interactions (DDIs) in chronic disease treatment. As healthcare advances, the prevalence of polypharmacy continues to rise, particularly among patients with complex conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension (PAH), and diabetes mellitus. The theoretical exploration within this research highlights the multifaceted impact of DDIs, which range from diminished drug efficacy to severe adverse effects, ultimately compromising patient outcomes and increasing healthcare costs.

The findings emphasize the necessity of integrating advanced clinical tools, such as drug interaction databases and decision support systems, to predict and mitigate the risks associated with DDIs. These tools enable healthcare providers to optimize treatment regimens by carefully selecting medications and adjusting doses to minimize harmful interactions. Furthermore, the importance of patient education is paramount; ensuring that patients are well-informed about their medication regimens can enhance adherence and reduce the likelihood of unintentional interactions.

This study also sheds light on the unique challenges faced by elderly patients, who are particularly vulnerable to the adverse effects of DDIs due to age-related changes in drug metabolism. Tailored therapeutic strategies and regular monitoring are crucial in this demographic to ensure safe and effective treatment.

In summary, managing DDIs is a dynamic and essential aspect of chronic disease care. Future research should focus on refining predictive models and enhancing interdisciplinary collaboration to improve patient safety and treatment outcomes. By addressing the complexities of DDIs, healthcare systems can move closer to achieving personalized and effective chronic disease management.

References

1. Hanlon, P., et al., *Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials.* 2023. **20**(6): p. e1004176.
2. Bellosta, S., A.J.E.O.o.D.M. Corsini, and Toxicology, *Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs.* 2024: p. 1-9.
3. Mandal, S., et al., *Natural Products As Sources of Drug Discovery: Exploration, Optimisation, and Translation Into Clinical Practice.* 2024. **6**(9): p. 2486-2504.

4. Villemure, S., et al., *The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions.* 2023. **19**(6): p. 329-332.
5. Suryaman, A., et al. *Risk of Adverse Drug-Drug Interactions in Heart Failure Patients with Co-morbidity Chronic Kidney Disease Prescribed Polypharmacy*. in *BIO Web of Conferences*. 2023. EDP Sciences.
6. Al-Worafi, Y.M., *Artificial intelligence and machine learning for drug safety*, in *Technology for drug safety: Current status and future developments*. 2023, Springer. p. 69-80.
7. Utami, I.K., et al., *Potential drug interactions in inpatients with chronic kidney disease at Undata Hospital, Palu City, Indonesia.* 2023. **2**(4): p. 243-248.
8. HV, A., et al., *Incidence, Patterns, and Severity of Potential Drug Interactions Among Cancer Patients on Chemotherapy in a Tertiary Care Hospital.* 2023. **14**(1): p. 35-40.
9. Bandeira, D.J.F.y.M.K.D.P.B.d.W.K.P.P.M., *orang, sekitar 29%, dan hanya 6 orang yang mengkonsumsi obat pada usia 21-25 tahun yaitu sebanyak 6%.* 2019. **65**(1): p. 19.
10. Turossi-Amorim, E.D., B. Camargo, and F.J.H.P. Schuelter-Trevisol, *Prevalence of potential pharmacological interactions in patients undergoing systemic chemotherapy in a tertiary hospital.* 2022. **57**(5): p. 646-653.
11. Saleem, A., et al., *Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: results from a retrospective analysis.* 2017: p. 71-77.
12. Koni, A.A., et al., *A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs.* 2022. **22**(1): p. 547.
13. Yu, J., et al., *Mechanisms and clinical relevance of pharmacokinetic-based clinical drug-drug interactions for drugs recently approved by the US Food and Drug Administration*, in *Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters*. 2020, Elsevier. p. 339-358.
14. Menditto, E., et al., *Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis.* 2019. **14**(2): p. e0210701.
15. Sun, D., et al., *Why 90% of clinical drug development fails and how to improve it?* 2022. **12**(7): p. 3049-3062.
16. Hanlon, J.T., et al., *Potential drug–drug and drug–disease interactions in well-functioning community-dwelling older adults.* 2017. **42**(2): p. 228-233.
17. Shetty, V., et al., *Evaluation of potential drug-drug interactions with medications prescribed to geriatric patients in a tertiary care hospital.* 2018. **2018**(1): p. 5728957.
18. Spanakis, M., et al., *Evaluation of Drug Interactions in Hospitalized Patients with Respiratory Disorders in Greece.* 2023. **91**(1): p. 74-92.
19. Kuemmerle, A., et al., *Recognition and management of clinically significant drug–drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study.* 2021. **76**(10): p. 2681-2689.
20. Bories, M., et al., *Drug–drug interactions in elderly patients with potentially inappropriate medications in primary care, nursing home and hospital settings: a systematic review and a preliminary study.* 2021. **13**(2): p. 266.
21. Adibe, M.O., P.C. Ewelum, and K.C.J.P.A.M.J. Amorha, *Evaluation of drug-drug interactions among patients with chronic kidney disease in a South-Eastern Nigeria tertiary hospital: a retrospective study.* 2017. **28**(1).
22. Onyedikachi, E.A., et al., *Evaluation of drug-drug interactions among chronic kidney disease patients of nephrology unit in the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State.* 2017. **8**(0): p. 49-53.
23. Valdenor, C., et al., *Clinical Variation in the Treatment Practices for Medication Nonadherence, Drug–Drug Interactions, and Recognition of Disease Progression in Patients with Chronic Cardiometabolic Diseases: A Cross-Sectional Patient Simulation Study among Primary Care Physicians.* 2022. **2022**(1): p. 6450641.